Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...
Amgen initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of Amgen (AMGN) with a Peer Perform rating. Published first on TheFly – the ultimate source for ...
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
devdiscourse10h
Global Health: Big Pharma Deals, Diabetes Epidemic, and Opioid Cases
A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...
Wall Street Indexes Dip With Focus on Trump Policies, Economic Data
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
STAT12h
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
devdiscourse13h
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
The Financial Express17h
Supreme Court rejects plea to mandate doctors to inform patients about drug side-effects
The Supreme Court on Thursday dismissed a plea seeking a direction to mandate doctors to inform patients all kinds of ...